Boston Scientific heads into its third-quarter report with an unusual setup: Wall Street no longer seems to believe the company's own numbers. After three consecutive cuts to full-year guidance, analysts have pushed their quarterly estimates beneath management's stated range. The question on October 28 is less whether the medical device maker can beat a lowered bar and more whether its Watchman and electrophysiology franchises have stopped deteriorating.

Consensus calls for earnings of $0.76 per share on revenue of $5.17 billion. That is up just 1.3% from $0.75 a year ago, with sales up only 2.1%. For a company that recently aspired to double-digit top-line growth, that is close to flat. It is also a steep step down from the second quarter's $0.86 on $5.44 billion. Management guided third-quarter EPS to $0.80 to $0.82, so the Street sits well below even the low end. The Earnings Whisper of $0.73 is lower still, so the informal bar is even easier to clear on paper. Either analysts expect another disappointment, or they are building in a cushion after watching full-year EPS guidance slide from $3.43 to $3.49 down to $3.28 to $3.32 in two revisions.

The second-quarter call explains the skepticism. The core business, roughly three quarters of revenue, looked healthy, with interventional cardiology up 15% and neuromodulation and endoscopy also strong. Management expects that base to grow about 6% in the back half. The trouble lies in the two former growth engines. Watchman went from a roughly 29% grower late last year to a forecast of flat to low single digits for 2026. Management expects second-half declines in the mid-to-high single digits as conflicting clinical data on left atrial appendage closure weighed on referrals. US electrophysiology was cut to flat to low single digits as the company lost more share than expected in a pulsed field ablation market that is already 80% to 85% penetrated. Management also lowered its weighted market growth estimate, dropped the 10%-plus long-range target and warned that 2027 revenue growth will lag the market with limited EPS growth.

This report is the first real check on whether those forecasts were finally conservative enough. Validation would look like US Watchman declining no worse than the guided range, signs that referral patterns are stabilizing, and US EP share holding near current levels. It would also help if international EP and Watchman, up 23% and 18% last quarter, keep cushioning the domestic slowdown. A challenge would come from Watchman falling faster than expected, further gross margin erosion beyond the already lowered outlook, or any hint that the base business is cooling. Management also introduced a roughly $500 million restructuring program, a TAVR option through its Mirus investment and the pending Penumbra deal. Updates on cost savings timing and Penumbra's expected margin dilution will shape how investors frame 2027.

Sentiment has soured noticeably, with bearish readings climbing to 44.5% from 26.6% ahead of the prior report. The stock has edged up 5.6% since the last release, two points better than the S&P 500. But that modest bounce follows a collapse. Last quarter's range ran from nearly $67 down to about $42, and shares now trade at $45.05, deep below the 200-day moving average near $59. That leaves the stock in the lower half of its post-earnings range of $41.39 to $52.99.

With expectations this depressed, hitting management's own $0.80 to $0.82 range would count as a meaningful beat. Still, a clean quarter alone is unlikely to repair the story. What matters most is whether Boston Scientific can hold its trimmed full-year outlook without a fourth cut. It would also help to show that the Watchman and US EP slowdown has found a floor. Without that evidence, any earnings beat will look like the product of a lowered bar rather than a business regaining its footing.